Science and Research

Effects of triple therapy on disease burden in patients of GOLD groups C and D: results from the observational COPD cohort COSYCONET

BACKGROUND: Randomized controlled trials described beneficial effects of inhaled triple therapy (LABA/LAMA/ICS) in patients with chronic obstructive pulmonary disease (COPD) and high risk of exacerbations. We studied whether such effects were also detectable under continuous treatment in a retrospective observational setting. METHODS: Data from baseline and 18-month follow-up of the COPD cohort COSYCONET were used, including patients categorized as GOLD groups C/D at both visits (n = 258). Therapy groups were defined as triple therapy at both visits (triple always, TA) versus its complement (triple not always, TNA). Comparisons were performed via multiple regression analysis, propensity score matching and inverse probability weighting to adjust for differences between groups. For this purpose, variables were divided into predictors of therapy and outcomes. RESULTS: In total, 258 patients were eligible (TA: n = 162, TNA: n = 96). Without adjustments, TA patients showed significant (p < 0.05) impairments regarding lung function, quality of life and symptom burden. After adjustments, most differences in outcomes were no more significant. Total direct health care costs were reduced but still elevated, with inpatient costs much reduced, while costs of total and respiratory medication only slightly changed. CONCLUSION: Without statistical adjustment, patients with triple therapy showed multiple impairments as well as elevated treatment costs. After adjusting for differences between treatment groups, differences were reduced. These findings are compatible with beneficial effects of triple therapy under continuous, long-term treatment, but also demonstrate the limitations encountered in the comparison of controlled intervention studies with observational studies in patients with severe COPD using different types of devices and compounds.

  • Zader, J. A.
  • Jörres, R. A.
  • Mayer, I.
  • Alter, P.
  • Bals, R.
  • Watz, H.
  • Mertsch, P.
  • Rabe, K. F.
  • Herth, F.
  • Trudzinski, F. C.
  • Welte, T.
  • Kauczor, H. U.
  • Behr, J.
  • Walter, J.
  • Vogelmeier, C. F.
  • Kahnert, K.

Keywords

  • Copd
  • Health care costs
  • Lung function
  • Symptoms
  • Triple therapy
Publication details
DOI: 10.1186/s12890-024-02902-4
Journal: BMC Pulm Med
Pages: 103 
Number: 1
Work Type: Original
Location: Assoziierter Partner, ARCN, BREATH, CPC-M, TLRC, UGMLC
Disease Area: COPD
Partner / Member: COSYCONET, DKFZ, JLU, KUM, MHH, PRI, Thorax
Access-Number: 38424530

DZL Engagements

chevron-down